Skip to main content
. 2020 Jul 17;123(7):1071–1077. doi: 10.1038/s41416-020-0979-3

Fig. 2. a) Progression-free survival and b) overall survival according to initial systemic anti-metastatic therapy of patients with hormone receptor-positive metastatic breast cancer.

Fig. 2

CI confidence interval, PFS progression-free survival, OS overall.